Business Context and Reporting Period
This Form 8-K is a current report filed by AspenBio Pharma, Inc. (not Riot Platforms, Inc., as indicated in the metadata) on July 8, 2008, covering events occurring on July 1, 2008. The filing addresses corporate governance changes, specifically the expansion of the Board of Directors and the appointment of a new director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and compensation arrangements rather than financial performance.
Material Changes
- Board Expansion: The Board of Directors expanded its size to nine members.
- New Appointment: Michael R. Merson was appointed to fill a vacancy on the Board, serving until the 2009 Annual Meeting of Shareholders.
- Committee Assignments: Mr. Merson was appointed to the Audit Committee and the Compensation Committee.
Guidance, Outlook, and Compensation
There is no financial guidance, outlook, or discussion of risks and contingencies in this filing. The document details the compensatory arrangements for the new director:
- Stock Options: Mr. Merson was granted options to acquire 65,674 common shares at an exercise price of $6.38 per share. These options vest annually in arrears over three years and expire in ten years.
- Cash Compensation: As an independent director, he will receive $1,000 per month in cash compensation.
Investor Verification Checklist
- Verify the correct registrant name is AspenBio Pharma, Inc., not Riot Platforms, Inc.
- Confirm the total number of Board members is now nine.
- Review the terms of the 2002 Stock Incentive Plan regarding the vesting schedule for the 65,674 options granted.
- Check the attached press release (Exhibit 99.1) for additional context on Mr. Merson's qualifications.